SCHEMBL4672850

SCHEMBL4672850

O=C(O)C(O)=CC(=O)c1ccn(Sc2ccccc2)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.37
LMNA P02545 3/20 0.37
MAPT P10636 3/20 0.37
NPSR1 Q6W5P4 3/20 0.37
PLIN1 O60240 1/20 0.37
HPGD P15428 1/20 0.37
HTT P42858 1/20 0.37
PLIN5 Q00G26 1/20 0.37
ABHD5 Q8WTS1 1/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
NFE2L2 Q16236 1/20 0.35
HDAC1 Q13547 2/20 0.34
HDAC2 Q92769 2/20 0.34
HDAC3 O15379 1/20 0.32
NCOR2 Q9Y618 1/20 0.32
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA9 Q16790 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4672848 1.00 ALDH1A1 (0.37) ALDH1A1LMNAMAPTNPSR1PLIN1
SCHEMBL4674942 0.75 NFE2L2 (0.33) ALDH1A1LMNAMAPTNPSR1PLIN1
SCHEMBL4673279 0.74 ALKBH2 (0.35) ALDH1A1LMNAMAPTNPSR1PLIN1
SCHEMBL27555830 0.73 SIRT1 (0.35) ALDH1A1LMNAMAPTHPGDMEN1
SCHEMBL4672842 0.72 PLIN1 (0.32) ALDH1A1LMNAMAPTNPSR1PLIN1
SCHEMBL4672840 0.72 PLIN1 (0.32) ALDH1A1LMNAMAPTNPSR1PLIN1
SCHEMBL3305728 0.71 NFE2L2 (0.64) ALDH1A1LMNAMAPTNPSR1PLIN1
SCHEMBL3305717 0.71 NFE2L2 (0.64) ALDH1A1LMNAMAPTNPSR1PLIN1
SCHEMBL3305722 0.71 NFE2L2 (0.64) ALDH1A1LMNAMAPTNPSR1PLIN1
SCHEMBL4674497 0.71 CYP2C19 (0.47) ALDH1A1MAPTNFE2L2HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 ALDH1A1 980/4885LMNA 659/4885MAPT 205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.